Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 8 Lymphoid 5 Plasma cell 3 Thoracic 2 Gynecologic 2 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 339 Nivolumab 305 Ipilimumab 274 Cyclophosphamide 195 aldesleukin 148 Interleukin-2 110 fludarabine phosphate 107 trametinib 85 Temozolomide 83 fludarabine 81 Dacarbazine 81 dabrafenib 77 Radiotherapy 75 Biopsy 75 Vemurafenib 71 Imiquimod 53 Bevacizumab 51 sargramostim 50 Magnetic Resonance Spectroscopy 50 Specimen Handling 49 Radiosurgery 49 Peripheral Blood Stem Cell Transplantation 49 Paclitaxel 49 Aminolevulinic Acid 49 binimetinib 48 Carboplatin 48 Blood Specimen Collection 47 cemiplimab 46 Cisplatin 45 3-ingenyl angelate 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

romiplostim × Dermatologic × Clear all

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡